Back grey_arrow_rt.gif
 
 
Shionogi - ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase
 
 
  1. IAC: Activity of Next Generation Integrase Inhibitor (INI) S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961) - (07/19/10)
 
Shionogi - ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor
 
21 July 2010
London, UK, 21 July 2010 - Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
 
This decision is based on promising results from two Phase IIb trials, SPRING-1 and VIKING, which are being presented this week at the XVIII International AIDS Conference in Vienna, Austria (Abstract Numbers THLBB205 & MOAB0105). These trials explored the efficacy of '572 in treatment-naïve HIV subjects as well as in treatment-experienced subjects resistant to raltegravir. Further study in Phase III is necessary to determine conclusively the safety, efficacy and resistance profile of '572.
 
"ViiV Healthcare is committed to developing promising new options for the treatment of HIV. As a once-daily, unboosted integrase inhibitor, '572 could be an important new therapy to help people living with HIV," stated Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare. "'572 has the potential to offer naïve and experienced patients a new option, one which in Phase II has shown positive antiviral activity and resistance results once a day. We hope to explore the potential further in the Phase III studies, which are expected to begin this year."
 
"We are very pleased with the progress of '572 in collaboration with ViiV Healthcare. Reaching the important milestone of initiating Phase III studies is a credit to the hard work and commitment of teams in both Shionogi and ViiV Healthcare. We look forward to starting the Phase III programme for '572 and demonstrating its potential to benefit HIV infected patients across the treatment spectrum," said Dr. Sapan Shah, President & CEO, Shionogi Inc.
 
About the Phase IIb Trials
 
SPRING-1 Study Design (Abstract THLBB205) SPRING-1 is an ongoing Phase IIb, multicenter, partially-blinded, dose-ranging study comparing '572 to efavirenz (EFV) in 205 treatment-naïve subjects. Individuals were randomized 1:1:1:1 to 10 mg, 25 mg or 50 mg of '572 or EFV 600 mg once daily in combination with either tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC). VIKING Study Design (Abstract MOAB0105) The VIKING study is a Phase IIb multicenter, open-label, single arm study designed to assess the antiviral activity, safety and tolerability of '572 in treatment-experienced, HIV-infected adult subjects with raltegravir (RAL) resistance as short term functional monotherapy, and over a 24-week treatment period with optimized background therapy. Genotypic and phenotypic changes in HIV integrase were also evaluated. The study enrolled 27 subjects with screening plasma HIV-1 RNA 1000c/mL showing genotypic resistance to RAL and at least two other antiretroviral classes. All subjects had RAL-associated mutations at screening. Subjects received '572 50mg QD while continuing their failing regimen (without RAL) to Day 11 when the background regimen was optimized, where feasible, and '572 continued.
 
About Shionogi-ViiV Healthcare
 
LLC '572 is the lead compound in Shionogi-ViiV Healthcare LLC. It is currently the only once-daily, unboosted integrase inhibitor in Phase IIb clinical development. Shionogi-ViiV Healthcare LLC is also developing second-generation integrase inhibitors, including S/GSK1265744, currently in Phase II development.
 
About ViiV Healthcare
 
ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline (NYSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
 
About Shionogi & Co., Ltd
 
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company is the originator of innovative medicines which have been successfully delivered to millions of patients worldwide. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Inc. headquartered in Florham Park, NJ, please visit www.shionogi-inc.com.
 
Enquiries:
 
UK Media Enquiries: Philip Thomson (020) 8047 5502 Claire Brough (020) 8047 5502 Rebecca Hunt (020) 8380 6275
 
US Media Enquiries: Marc Meachem (919) 483 5005
 
GSK European Analyst/Investor Enquiries: David Mawdsley (020) 8047 5564 Sally Ferguson (020) 8047 5543 Gary Davies (020) 8047 5503
GSK US Analyst/ Investor Enquiries: Tom Curry (215) 751 5419 Jen Hill Baxter (215) 751 7002
Shionogi & Co., Ltd. Enquiries Corporate Communications +81 6 6209 7885
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org